Ermeza is owned by Mylan.
Ermeza contains Levothyroxine Sodium.
Ermeza has a total of 1 drug patent out of which 0 drug patents have expired.
Ermeza was authorised for market use on 29 April, 2022.
Ermeza is available in solution;oral dosage forms.
The generics of Ermeza are possible to be released after 27 February, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9345772||MYLAN||Liquid levothyroxine formulations|| |
(11 years from now)
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 29 April, 2022
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic